Drug Action & Receptor Pharmacology

← Back to Domain-Specific Families

Abstractions about how drugs act on and interact with biological targets, covering dose-response concepts (efficacy, potency, partial agonism), receptor and enzyme mechanisms (receptor antagonism, enzyme induction and inhibition, reuptake inhibition), and interaction or tolerance phenomena like pharmacokinetic interactions and tachyphylaxis.

16 abstractions in this family — domain-specific abstractions that sit near one another in structural-signature space (k-means over structural-signature embeddings). Each is shown with its short description.

• Efficacy — Separate the maximum effect a drug can produce at its target under full engagement (the ceiling, E_max) from the dose needed to approach it (potency, EC50), rooting that ceiling in the agent's intrinsic activity so a ceiling problem cannot be fixed by escalation.
• Environmental Exposure Modeling — Estimate a receptor's external contact with an environmental agent by combining agent levels in encountered settings with time, activity, and contact pathways.
• Enzyme Induction — The phenomenon in which a xenobiotic binds a nuclear receptor and raises transcription of specific metabolizing enzymes, enlarging the catalytic pool over days so it clears itself and every co-substrate sharing those isoforms faster.
• Enzyme Inhibition — A small molecule slows an enzyme by occupying or distorting its catalytic site, and the binding mode it uses fixes how reversible, surmountable, and durable the block will be.
• Metabolic Response to Injury — A systemic, time-varying endocrine, inflammatory, and metabolic response organized by tissue injury.
• P-i mechanism — The p-i mechanism explains drug hypersensitivity through direct off-target interaction between a drug and immune receptors that activates T cells.
• Partial Agonist — A ligand that binds and activates a receptor but with intrinsic efficacy between zero and one, so even at full occupancy it produces a submaximal response — acting as an agonist when alone and a functional antagonist when a full agonist is present.
• Pharmacodynamic Antagonism — Diagnose why two co-administered drugs blunt each other by locating the opposition at the receptor or effector rather than at the concentration layer, then classify its binding geometry to read off whether more dose can overcome it.
• Pharmacodynamics — Pharmacodynamics studies and models what a drug does to a biological system by relating concentration or exposure at sites of action to biochemical, physiological, therapeutic, and toxic effects over time.
• Pharmacokinetic Interaction — Locate a drug-interaction failure at the exposure layer — one substance altering another's absorption, distribution, metabolism, or excretion so its concentration-time profile shifts at an unchanged dose — rather than as opposition at a shared receptor.
• Pharmacological Interaction — Treat two co-present pharmacological agents as a coupled system when one changes the other's exposure or action, or their joint effect departs from the effect expected if each operated independently; then localize the coupling to the pharmacokinetic exposure layer or the pharmacodynamic effect layer.
• Potency — Quantify how much drug a given effect costs by reading one coordinate off the dose-response curve: the dose that produces half the maximal response (the ED50), so a lower value means less drug suffices.
• Receptor antagonist — A receptor antagonist is a type of receptor ligand or drug that blocks or dampens a biological response by binding to and blocking a receptor rather than activating it like an agonist.
• Reuptake — Transporter-mediated removal of a released neurotransmitter from extracellular synaptic space into a neuron or glial cell.
• Reuptake inhibitor — An agent that reduces transporter-mediated removal of a signaling molecule, altering its extracellular or vesicular availability according to the transporter and inhibition site involved.
• Tachyphylaxis — Tachyphylaxis (from Ancient Greek , 'rapid', and , 'protection') is a medical term describing an acute, sudden decrease in response to a drug after its administration (i.e., a rapid and short-term onset of drug tolerance).